A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral Orforglipron Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)
This study will investigate the efficacy and safety of once daily oral orforglipron in adult participants with obesity or overweight with weight-related comorbidities. The study has two phases: a main phase and an extension phase. The main phase of the study lasted 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Inclusion Criteria:
Have a BMI
≥30.0 kilogram/square meter (kg/m²),
≥27.0 kg/m² and presence of at least 1 of the following weight-related comorbidities (treated or untreated) at screening:
Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight.
Exclusion Criteria:
Chandler, Arizona 85225, United States
Sun City West, Arizona 85375, United States
Hyattsville, Maryland 20782, United States
Troy, Michigan 48098, United States
Luoyang Shi, Henan 471003, China
Bangalore, Karnataka 560002, India
Aki-gun, Hiroshima 735-0017, Japan
Suita-shi, Osaka 565-0853, Japan
Adachi-ku, Tokyo 120-0022, Japan
Chuo-ku, Tokyo 103-0027, Japan
Chuo-ku, Tokyo 103-0027, Japan
Chuo-ku, Tokyo 104-0031, Japan
Meguro-ku, Tokyo 153-0053, Japan
Setagaya-ku, Tokyo 155-0031, Japan
Shinjuku-ku, Tokyo 160-0008, Japan
Namdong-gu, Incheon-gw 21565, South Korea
Ferrol, A Coruña [La Coruña] 15405, Spain
Kaohsiung Niao Sung Dist, Kaohsiung 83301, Taiwan